The management of cancer patients has changed due to the considerably more frequent
use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side …

Use of immune checkpoint inhibitors in cancer treatment has increased vastly over the past
decade, as both single and combination agent therapies. While having a positive impact on …

Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-
cell proteins involved in the activation of immune response toward malignancies. Their …

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated
with significant autoimmune endocrinopathies that pose both diagnostic and treatment …

Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …

Immune checkpoint inhibitors (ICIs) are novel anticancer agents, recently introduced with the
aim of boosting the immune response against tumors. ICIs are monoclonal autoantibodies …

Context: In recent years, progress has been made in cancer immunotherapy by the
development of drugs acting as modulators of immune checkpoint proteins, such as the …

Immune checkpoint inhibitors (CPIs) reverse immune suppression that is thought to allow
malignant growth. Despite remarkable efficacy in a subset of cancers, their use is …

Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for
numerous malignancies. However, due to their association with autoimmunity, ICIs have …

Immune checkpoint inhibitors have recently become a cornerstone for the treatment of
different advanced cancers. These drugs, represented mainly by monoclonal antibodies anti …